Therapeutics News and Research

RSS

Synageva BioPharma seeks FDA orphan drug designation for SBC-102 enzyme replacement therapy

Synageva BioPharma Corp., a privately held biopharmaceutical company, today announced its filing with the U.S. Food and Drug Administration (FDA) requesting orphan drug designation for its program, SBC-102. This program is an enzyme replacement therapy in preclinical development to treat lysosomal acid lipase (LAL) deficiency, also known as Wolman disease or cholesteryl ester storage disease (CESD), a condition for which there is currently no effective treatment.

4 May 2010

Cornerstone Therapeutics first-quarter total net revenue increases 19% to $36.4 million

Cornerstone Therapeutics Inc. today reported financial results for the first quarter ended March 31, 2010.

4 May 2010

Rigel Pharmaceuticals reports net loss of $22.3M for first-quarter 2010

Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2010.

4 May 2010

Amorfix Life Sciences detects AD-associated aggregated Beta-amyloid in blood plasma

Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases such as Alzheimer's disease (AD), announced today the detection of the AD-associated aggregated Beta-amyloid (ABeta), the hallmark of AD, in the blood from the most-frequently-used animal model of AD. The assay detects both oligomeric and fibrillar aggregates of ABeta, which are generally considered to be the toxic forms and major contributors to brain dysfunction in AD.

4 May 2010

Phase 2 clinical trial data of voreloxin to be presented at 2010 ASCO Annual Meeting: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Sunesis Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

4 May 2010

Alnylam Biotherapeutics presents new data on RNAi technologies at Cell Culture Engineering XII

Alnylam Biotherapeutics, a division of Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the presentation of new data at the Cell Culture Engineering XII conference held in Alberta, Canada from April 25 - 30, 2010. Alnylam Biotherapeutics was formed by Alnylam to develop RNAi technologies for application in manufacturing processes for biotherapeutic products, including recombinant proteins and monoclonal antibodies.

4 May 2010

Ocera Therapeutics presents Phase 2 proof-of-concept study results of AST-120 in non-constipating IBS

Ocera Therapeutics, Inc. presented results yesterday from a Phase 2 proof-of-concept study of AST-120 (spherical carbon adsorbent) in the treatment of patients with non-constipating Irritable Bowel Syndrome (IBS) at DDW, the annual meeting of the American Gastroenterological Association. Data showed that subjects treated with AST-120 responded in a consistent manner with reduction in pain better than placebo at week four and at week eight, the primary time point for analysis. The company plans to initiate a Phase 2b study evaluating AST-120 in non-constipating IBS.

4 May 2010

BioMarker Strategies receives $1M NCI grant funding to develop SnapPath live tumor cell testing system

BioMarker Strategies announced today that the National Cancer Institute (NCI) has approved the first $1 million in Phase II funding for the company's Small Business Innovative Research (SBIR) contract to develop the SnapPath™ live tumor cell testing system. The company is developing the SnapPath™ system to better enable drug companies to stratify patients in clinical trials, as well as assist oncologists in determining the most effective targeted drug treatment for their cancer patients.

4 May 2010

Targacept, AstraZeneca expand TC-5619 development program to include ADHD, Alzheimer's disease

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced an amendment to its 2005 collaboration agreement with AstraZeneca expanding the TC-5619 development program. In addition to the current development of TC-5619 in cognitive dysfunction in schizophrenia (CDS), the amended terms provide for parallel development in attention deficit/hyperactivity disorder (ADHD) and potentially Alzheimer's disease.

3 May 2010

ImmunoCellular Therapeutics seeks FDA orphan drug status for ICT-107 dendritic-cell based vaccine for GBM

ImmunoCellular Therapeutics announced today it has filed an orphan drug application with the U.S. Food and Drug Administration (FDA) for its cancer treatment candidate ICT-107. ICT-107 is a dendritic-cell based cancer vaccine product which targets glioblastoma multiforme (GBM), the most prevalent, aggressive and malignant form of primary brain tumors.

3 May 2010

Curis completes enrollment in Phase I clinical trial of CUDC-101 HDAC, EGFR and HER2 inhibitor

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has successfully completed enrollment and treatment of the last patient in its Phase I clinical trial of CUDC-101, Curis' first-in-class HDAC, EGFR and HER2 inhibitor.

3 May 2010

BioTime acquires ES Cell International

BioTime, Inc., a biotechnology company that develops and markets products in the field of human stem cells and regenerative medicine, today announced that it has completed its acquisition of the Singapore company ES Cell International Pte Ltd.

3 May 2010

Alnylam Pharmaceuticals announces EPO intent to grant notification for patent series covering RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has issued a notification of an intent to grant for the "Manoharan II" patent series (EP Application No 04 718 537), titled "Therapeutic Compositions." The new patent includes 16 claims covering compositions and methods, including pharmaceutical compositions, for chemically modified siRNAs containing phosphorothioate and 2′-O-alkyl modifications without any siRNA length restrictions.

3 May 2010

Investment report on Spectrum Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Spectrum Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

3 May 2010

Scripps Research Institute awarded grant to design assays for exploring potential target for obesity, Type 2 diabetes

The Scripps Research Institute has been awarded a $1.3 million grant by the National Institutes of Health (NIH) to develop a series of tests at its Florida campus to help explore the potential of a protein that has emerged as a highly attractive target for the treatment of obesity and Type 2 diabetes.

3 May 2010

Roche's xCELLigence System helps study cell viability, cell death while testing cytotoxic compounds

Monitoring of cell viability and toxicity are critical to many areas of biological and biomedical research. This is true for understanding the molecular and biochemical pathways regulating cell viability, for developing therapeutic agents which modulate cell viability and for identifying potential cytotoxic side effects of potential therapeutic agents.

3 May 2010

FDA approves continuation of Phase IIb clinical trial for superficial bladder cancer

Tikcro Technologies Ltd. today announced that BioCancell Therapeutics, Inc., concluded the first 18 patient group treated pursuant to a Phase IIb clinical trial of the drug candidate BC-819 for use in superficial bladder cancer. These patients had not responded to conventional treatment.

3 May 2010

MicroStockProfit.com releases investment report featuring Cardium Therapeutics

MicroStockProfit.com announces an investment report featuring Cardium Therapeutics Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

30 Apr 2010

Repros Therapeutics receives FDA guidance for lifting clinical hold status of Proellex

Repros Therapeutics Inc. today announced that a teleconference was held with the FDA to review the clinical hold status of Proellex®. Previously clinical studies were stopped due to findings of changes in liver enzymes at higher doses of the oral drug resulting in serious adverse events. Proellex is being studied as a treatment for uterine fibroids and endometriosis.

30 Apr 2010

Acorda Therapeutics reports AMPYRA gross sales of $3.4 million for first-quarter 2010

Acorda Therapeutics, Inc. today announced its financial results for the first quarter of 2010.

30 Apr 2010

Therapeutics News and Research

Synageva BioPharma seeks FDA orphan drug designation for SBC-102 enzyme replacement therapy

Cornerstone Therapeutics first-quarter total net revenue increases 19% to $36.4 million

Rigel Pharmaceuticals reports net loss of $22.3M for first-quarter 2010

Amorfix Life Sciences detects AD-associated aggregated Beta-amyloid in blood plasma

Phase 2 clinical trial data of voreloxin to be presented at 2010 ASCO Annual Meeting: MicroStockProfit.com

Alnylam Biotherapeutics presents new data on RNAi technologies at Cell Culture Engineering XII

Ocera Therapeutics presents Phase 2 proof-of-concept study results of AST-120 in non-constipating IBS

BioMarker Strategies receives $1M NCI grant funding to develop SnapPath live tumor cell testing system

Targacept, AstraZeneca expand TC-5619 development program to include ADHD, Alzheimer's disease

ImmunoCellular Therapeutics seeks FDA orphan drug status for ICT-107 dendritic-cell based vaccine for GBM

Curis completes enrollment in Phase I clinical trial of CUDC-101 HDAC, EGFR and HER2 inhibitor

BioTime acquires ES Cell International

Alnylam Pharmaceuticals announces EPO intent to grant notification for patent series covering RNAi therapeutics

Investment report on Spectrum Pharmaceuticals

Scripps Research Institute awarded grant to design assays for exploring potential target for obesity, Type 2 diabetes

Roche's xCELLigence System helps study cell viability, cell death while testing cytotoxic compounds

FDA approves continuation of Phase IIb clinical trial for superficial bladder cancer

MicroStockProfit.com releases investment report featuring Cardium Therapeutics

Repros Therapeutics receives FDA guidance for lifting clinical hold status of Proellex

Acorda Therapeutics reports AMPYRA gross sales of $3.4 million for first-quarter 2010

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News